Reproduction number <i>R</i>(<i>t</i>) for the duration of the simulation. by Sebastian A. Müller (10688740)

Simulations with reductions of activity participation as obtained from mobility data. by Sebastian A. Müller (10688740)

Normalized contact intensities <i>ci</i>′, relative to the contact intensity at home, . by Sebastian A. Müller (10688740)

Outdoors fraction for activities of type leisure, depending on the temperature of each day. by Sebastian A. Müller (10688740)

Final model. by Sebastian A. Müller (10688740)

How duration (in hours) translates into the infection probability for two different contact intensities. by Sebastian A. Müller (10688740)

Disease progression model. by Sebastian A. Müller (10688740)

Contributions to <i>R</i> by activity type and intervention according to our model. by Sebastian A. Müller (10688740)

Average time consumption of out-of-home activities. by Sebastian A. Müller (10688740)

Disease import over time. by Sebastian A. Müller (10688740)

Unrestricted base case. by Sebastian A. Müller (10688740)

Events for travel. by Sebastian A. Müller (10688740)

Pharmacodynamic Profile of CCX168 in Healthy Human Volunteers. by Pirow Bekker (392139)

“…(A) C5a-induced upregulation of CD11b on the surface of neutrophils in whole blood collected in the placebo group (●), and at 2 hours (♦) and 24 hours (◊) after a single dose of 10 mg CCX168, at 2 hours (▲) and 12 hours (Δ) after a single dose of 30 mg CCX168, and 2 hours (■) and 12 hours (□) after a single dose of 100 mg CCX168. …”

Anti-TNF antibody hampered the rIFNγ-induced augment of U-87 MG cells infection by <i>T</i>. <i>cruzi</i>. by Glaucia Vilar-Pereira (686134)

Systemic TUDCA administraton decreases photoreceptor cell loss in RD. by Dimosthenis Mantopoulos (343471)

Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial by Tracey L. Sletten (749784)

“…Following 1-wk baseline, clinically diagnosed DSWPD patients with delayed melatonin rhythm relative to DBT (salivary dim light melatonin onset [DLMO] after or within 30 min before DBT) were randomised to 4-wk treatment with 0.5 mg fast-release melatonin or placebo 1 h before DBT for at least 5 consecutive nights per week. …”

Top 10 important features according to the average decrease in Gini index over the 18 training models (features with a higher decrease tend to better split mixed nodes into single... by Remy Klaassen (3903154)

Effects of conivaptan on brain water content (BWC), blood-brain-barrier (BBB) disruption, plasma and urine sodium and osmolality. by Emil Zeynalov (596088)

“…Following MCAO, Evans Blue (EB) extravasation index (I/C) was increased in vehicle treated mice, and reduced in conivaptan treated mice, naïve, n = 5, vehicle, n = 8, Conivaptan 0.2 mg, n = 8. (C, D) Conivaptan treatment of 0.2 mg resulted in an elevation of plasma sodium and osmolality, and decreased urine sodium and osmolality due to aquaresis. …”

Effects of tolvaptan on brain water content (BWC), plasma and urine sodium and osmolality. by Emil Zeynalov (596088)

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-co... by Tadao Akizawa (316095)

“…Adverse events were observed in 30%–50% of patients (all groups). Incidence of adverse events was similar among all groups except for decreased calcium, which occurred more frequently in the evocalcet 2 mg and cinacalcet groups.…”